Andrew Hankinson in Monroeville, Pennsylvania

Additional Medical Specialties Include:
MICROGRAPHIC DERMATOLOGIC SURGERY (MDS)

Medical School: Pennsylvania State University College Of Medicine
Graduation Year: 2013
The Primary Medical Specialty for Andrew Hankinson is listed as: Dermatology
Approximate Years of Experience: 11
PAC (PECOS ID)#: 1759682917
NPI #: 1487099057
NPI Created On: 05/08/2013
NPI Last Updated Listed as: 04/01/2022
Primary Taxonomy Code: 207N00000X
License Number:
MD461844
Listed Gender: Male

Forms of insurance accepted by include, but are not limited to:

• Capital Advantage Assurance Company
• Highmark Health Insurance Company
• Highmark Inc.
• First Priority Health
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Tangential biopsy of single skin lesion
2. Removal of malignant growth (1.1 to 2.0 centimeters) of the trunk, arms, or legs
3. Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs
4. Repair of wound (2.6 to 5.0 centimeters) of face, ears, eyelids, nose, lips, and/or mouth
5. Repair of wound (2.6 to 7.5 centimeters) of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, and/or feet
6. Destruction of skin growth
7. Destruction of 2-14 skin growths
8. Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals (first stage, up to 5 tissue blocks)
9. Removal and microscopic examination of growth of the head, neck, hands, feet, or genitals
10. Pathology examination of tissue during surgery
11. Application of light and light-sensitive drugs to aid destruction of premalignant skin growths, per day
12. New patient office or other outpatient visit, typically 20 minutes
13. New patient office or other outpatient visit, typically 30 minutes
14. Established patient office or other outpatient visit, typically 10 minutes
15. Established patient office or other outpatient visit, typically 15 minutes
16. Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg)